From Schizophrenia to Cancer | GenomeWeb

From Schizophrenia to Cancer

Premium

A new study in Cell published by researchers at McMaster University suggests that a drug commonly used to treat ailments like schizophrenia might also be beneficial for cancer patients, reports PsychCentral's Rick Nauert. The drug, a dopamine receptor antagonist, seems to influence cancer stem cells to differentiate into more benign cell types, Nauert says.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.

Jeremy Berg is to be the next editor in chief of Science magazine.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.